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Introduction
Induced sputum analysis has become an im-
portant direct, non-invasive method for the assess-
ment of airway inflammation.
Since the first description of a standardised
method [1] there has been an impressive increase
of papers in which researchers have used induced
sputum to study various aspects of airway inflam-
mation. In order to harmonise the different tech-
niques used worldwide a standardised methodolo-
gy of sputum induction and processing was issued
in 2002 by a European Respiratory Society Task
Force [2].
Several studies have shown that evaluation of
induced sputum cells is a reproducible and valid
technique [3-5]. In particular, one study evaluated
the reproducibility of cell counts on cytospins and
fluid phase measurements in selected portion of in-
duced sputum. A high reproducibility within sam-
ple, between sample and between examiners for all
types of cells was reported [3]. Moreover, mea-
surements between different airway diseases were
successfully detected, thus confirming the validity
of the technique [3].
Reference values and the distribution of cell
counts in induced sputum have been provided in a
large number of healthy volunteers [6, 7]. The in-
duced sputum was found rich in macrophages and
neutrophils and poor in eosinophils, lymphocytes
and epithelial cells. These parameters can be used
in comparisons with induced sputum cell counts of
subjects with airway inflammation [6].
Furthermore, sputum induction has been found
to be a simple, safe and well tolerated procedure
even in patients with severe lung disease and hav-
ing exacerbations. However, it has been recom-
mended that experienced personnel carry out the
operation and that they apply standard operating
procedures, to be aware of the degree of airway
obstruction, to use a modified protocol for subjects
with severe airway obstruction and to assess lung
function and symptoms during sputum induction
procedure [8].
Over the last 15 years sputum analysis has be-
come one of the most referenced methods to assess
airway inflammation in research and clinical prac-
tice [9]. In particular, it has been useful in the char-
acterisation of the type and the extent of airway in-
flammation in asthma, Chronic Obstructive Pul-
monary Disease (COPD) and chronic cough, and
has provided much useful knowledge of their in-
flammatory processes [9].
Although the induced sputum technique has
been broadly used in asthma and COPD it may be
helpful in the diagnosis of other lung diseases such
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diseases assessed by induced sputum. S. Dragonieri, 
O. Tongoussouva, A. Zanini, A. Imperatori, A. Spanevello.
During recent years there has been a growing interest
in using non-invasive biomarkers to understand and mon-
itor the airway inflammation in subjects with respiratory
tract disorders.
To date, the best validated and performing non-inva-
sive biomarkers are measures of inflammation in induced
sputum in both cellular and fluid phase, which can pro-
vide biological insights into the pathogenesis of respirato-
ry diseases such as asthma and chronic obstructive pul-
monary disease.
The purpose of this review is to examine the principal
literature on the different markers of inflammation in pul-
monary diseases assessed by induced sputum analysis in
either cellular or fluid phase.
Monaldi Arch Chest Dis 2009; 71: 3, 119-126.
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as lung cancer, cystic fibrosis and interstitial lung
diseases.
The aim of the present paper was to review the
principal literature on the different markers of inflam-
mation in pulmonary diseases assessed by induced
sputum analysis in both cellular and fluid phase.
Asthma
Since the first study in 1992 [1] many authors
have validated the measurements of both cellular
and soluble components related to asthma.
These studies have significant in the compre-
hension of the inflammatory processes that play a
role in the development and maintenance of the
disease.
Therefore there has recently been a growing
interest in the application of induced sputum for
monitoring and optimisation of asthma control.
Cellular composition
Sputum eosinophilia is a typical feature of asth-
ma. Sputum eosinophil count is a validated bio-
marker for the assessment of airway inflammation
that can be easily performed even in clinical set-
ting. Asthmatic patients with sputum eosinophilia
have a positive response to corticosteroids, even in
ex-smokers and current smokers [10].
Increased sputum eosinophils are associated to
a thickening of the greater basement membrane
[11]. Some authors have recently suggested that
sputum eosinophilia may reflect inadequate con-
trol airway inflammation, resulting in an increased
risk of exacerbation [12-14].
Conversely, a considerable percentage of corti-
costeroid-free asthmatics (ranging from 25 to
55%) show a neutrophilic inflammation [15-17].
This condition is called non-eosinophilic asthma
and it is important to identify because it is associ-
ated with a poor response to corticosteroids [16].
Fluid-phase mediators
Although the validity and reproducibility of
several techniques has not been assessed yet, many
potential biomarkers can be examined in induced
sputum supernatant (table 1).
Fig. 1. - Sputum induction.
Table 1. - Markers of airway inflammation in cellular and fluid phase in each pulmonary disease. For abbreviations
legend see text
Asthma COPD Cystic fibrosis Sarcoidosis
CELLULAR PHASE ↑ Eosinophils ↑ Neutrophils ↑ Total cell count ↑ Lymphocytes
↑ Neutrophils (non-eosinophilic asthma) ↑ Eosinophils (likely overlap with asthma. ↑ Neutrophils
Better response to corticosteroids)
↑ CD8+ T-lymphocytes
FLUID PHASE ↑ ECP ↑ IL-8 ↑ IL-8
↑ MPO ↑ IL-6 ↑ NE
↑ Albumin ↑ TNF-α
↑ Fibrinogen ↓ IL-10
↑ Nonkinase plasminogen activator ↑ Leptin
↑ Plasminogen activator inhibitor ↑ MPO
↑ Neurokinin A ↑ HNL
↑ IL-8 ↑ NE
↑ IL-13 ↑ ECP
↑ CYS-LTs ↑ EPO
↑ 8-Isoprostane ↑ LTB-4
↑ MMP-9/TIMP ratio ↑ GRO-a
↑ MCP-1
↑ GM-CSF
↑ MMP-1, -8, -9, -12
↑ Hyaluronan
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Eosinophil Cationic Protein (ECP) and Myelo-
peroxidase (MPO) are granulocyte proteins that are
well correlated with eosinophil cell count [18] and
decrease after anti-nflammatory treatment [19, 20].
Levels of leakage markers such as albumin and
fibrinogen were found increased in subjects with
asthma compared to healthy subjects [4] and their
concentrations are related to asthma severity [21, 22].
Moreover, recent studies showed that asthmat-
ic subjects have increased concentrations of nonk-
inase plasminogen activator and plasminogen acti-
vator inhibitor [23] compared to controls and Neu-
rokinin A significantly raises during exacerbations
[24]. Interleukin-8 (IL-8) is a neutrophil chemoat-
tractant which has been shown to be increased dur-
ing asthma exacerbations [25] and in patients with
severe persistent asthma [17], suggesting a role for
monitoring asthma exacerbations and assessing the
effectiveness of a medication in severe asthmatics.
IL-13 is another cytokine whose levels were found
higher in asthmatics than controls [26]. However it
occurred in less than 50% of asthmatics and no
correlation with asthma severity was found [26].
Cysteinyl leukotrienes (Cys-LTs) and 8-iso-
prostane are inflammatory mediators involved in
the pathophysiology of asthma [27, 28]. Both have
been extensively studied during recent years [29,
30] and their concentration correlates with severi-
ty of disease and are relatively unaffected by corti-
costeroids [31-33]. However 8-isoprostane was
not found to be increased in newly diagnosed sub-
jects with asthma [34]. Finally, asthmatic subjects
show a higher level of Matrix metalloproteinasis-9
(MMP-9) [35-39]. In the process of remodelling an
impairment in the balance between MMP-9 and its
counterpart tissue inhibitor of metalloproteinases
(TIMP) occurs. Indeed, asthmatic subjects have an
increase in MMP-9/TIMP ratio that is related to
the disease severity [35, 36, 40].
Chronic obstructive pulmonary disease
Induced sputum has been broadly used to in-
vestigate the inflammatory mechanism of COPD
and it has provided considerable information about
the inflammatory process of this disease. Although
patients with COPD expectorate spontaneously it is
suggested to perform induced sputum, since spon-
taneous sputum may contain a high amount of dead
cells [4] that may lead to errors during cell count
and fluid-phase mediators measurements [41, 42].
Cellular composition
An increase in the percentage of neutrophils is
the typical feature in subjects with COPD [43-45].
Neutrophils are increased compared to asympto-
matic smokers and there is a negative correlation
between neutrophil counts and FEV1 [46]. This in-
dicates that neutrophils are relevant in the patho-
genesis of COPD.
Some COPD patients show an increased num-
ber of eosinophils, indicating a likely overlap with
asthma, and this seems to predict a better response
to bronchodilators and inhaled corticosteroids [47].
Moreover, CD8+ T-cells are increased in in-
duced sputum of patients with COPD [48]. It has
been shown that the CD8+ T-cells involved in
COPD are type 1 [49]. Type 1 cells play a role in
the response to viral infections that are frequent in
patients with COPD [50].
Inflammatory mediators
Many inflammatory mediators have been
analysed in the fluid-phase of induced sputum
(table 1). Several cytokines, chemokines,
eicosanoids, markers of oxidative stress show an
increase in COPD compared to asymptomatic
smokers, with a further increase during exacerba-
tions. In particular, inflammatory cytokines, in-
cluding Interleukin-8 (IL-8), Interleukin 6 (IL-6)
and Tumour Necrosis Factor-alpha (TNF-α) have
been extensively studied and reported increased in
sputum of COPD patients compared to normal
smokers [51-54] and their concentrations are relat-
ed to the severity of the disease [55]. However the
inflammatory cytokine Interleukin-10 (IL-10) are
reduced in sputum of healthy smokers and, to a
greater extent, in smokers with COPD [56], sug-
gesting a role of the imbalance between cytokines
with different properties in the smoke-induced
lung damage.
Induced sputum of patients with COPD shows
an increase of Leptin that is correlated with other
inflammatory markers including TNF-α and C-re-
active protein (CRP) [57].
Moreover, sputum fluid-phase in COPD shows
an increase in neutrophilic and eosinophilic granu-
locyte proteins such as Myeloperoxidase (MPO),
Human Neutrophil Lipocalin (HNL), Neutrophil
Elastase (NE) and Eosinophilic Cationic Protein
(ECP), Eosinophil Peoxidase (EPO) and chemoat-
tractants like Leukotriene B-4 (LTB-4), Growth
Related Oncogen-a (GRO-a), Monocyte Chemo-
tactic Protein-1 (MCP-1) and Granulocyte
Macrophages-Colony Stimulating Factor (GM-
CSF) [58-60].
Increased sputum concentration of proteins,
including neutrophil Elastase and Metallopro-
Fig. 2. - Sample of induced sputum.
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teinases 1,8,9 and 12 (MMP-1, -8, -9 and 12) as
well as decreased Antiproteasis (TIMP-1) strongly
support the oxidant-antioxidant and proteinase-an-
tiproteinase imbalance hypothesis for the patho-
genesis of COPD [59, 61-63].
Finally, higher levels of Hyaluronan indicate a
leakage in the extracellular matrix in COPD [64].
Cystic fibrosis
Cystic fibrosis is the most common lethal ge-
netically inherited disease characterised by a self
perpetuating cycle of airway obstruction, chronic
bacterial infection, and vigorous inflammation that
results in bronchiectasis, progressive obstructive
lung disease, and marked shortening of life ex-
pectancy [65]. Airway inflammation plays an im-
portant role in the progression of cystic fibrosis.
Thus, inflammatory biomarkers in sputum of pa-
tients with cystic fibrosis can be utilised for moni-
toring disease progression and evaluation of treat-
ment.
Airway inflammation in cystic fibrosis is char-
acterised by the presence of abundant amounts of
neutrophils, neutrophil products, as well as epithe-
lial cells, macrofages, T lymphocytes, B lympho-
cytes, dendritic cells and mast cells [66]. Sputum
has been used extensively to evaluate airway in-
flammation in cystic fibrosis. Various markers in-
cluding inflammatory cells, cytokines, cytokine
antagonists, neutrophil chemoattractants, proteas-
es, antiproteases, markers of oxidative stress, an-
tioxidants, plasma exudates markers, antimicrobial
proteins, antimicrobial peptides, nitric oxide
metabolites and pathway, eicosanoids, mucins, ad-
hesion molecules, markers of structural airway in-
jury and components of signaling cascades that
can be measured in sputum were suggested [66].
Fig. 3. - Sputum processing. Proper facilities and well-trained personnel are required.
Fig. 4. - Cytospin of a normal subject. A higher percentage of
Macrophages is the typical feature. Magnification 40X.
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The most important indicators of airway inflam-
mation in sputum of patients with cystic fibrosis
are the increase of total cell counts, as well as neu-
trophil counts and increased level of interleukin-8
[67]. Inflammatory markers can be studied in
spontaneously produced and induced sputum. Ad-
ministration of sputum induction is a good solution
to evaluate airway inflammation in patients who
are not able to produce sputum spontaneously. To-
tal cell counts, as well as neutrophil counts in in-
duced sputum are significantly increased in com-
parison with sputum obtained from healthy indi-
viduals [68]. However, the degree of this inflam-
mation is not significantly different from those
evaluated in patients with cystic fibrosis who have
a productive cough and can produce sputum spon-
taneously [68]. Similarly, IL-8 levels and neu-
trophil elastase activity are similar in spontaneous-
ly produced and induced sputum [68]. This indi-
cates that the analysis of induced and/or sponta-
neously produced sputum can provide relevant
useful information for evaluation and monitoring
of patients with cystic fibrosis. However, other
studies are required to further investigate relation-
ship between variability of inflammatory biomark-
ers and disease severity.
Lung cancer
Lung cancer has an important clinical and so-
cio-economical significance, as it is the most com-
mon and the most lethal cancer in many countries
of the world. Several studies have documented the
possibility of diagnosing lung cancer by using spu-
tum cytology [69-71]. A method based on identifi-
cation of biomarkers of lung cancer in the sputum
of suspects can be performed for early diagnosis of
this pathology. This can be very useful especially
in patients affected by early stage of lung cancer
when traditional methods of diagnosis are not yet
able to reveal the disease. For example, sputum cy-
tology is useful in finding early central lung can-
cer, particularly squamous cell carcinoma in situ
and microinvasive squamous cell carcinoma [70].
However, most of the studies demonstrated that
sputum cytology had low sensitivity in discovering
clinical lung cancer [71]. The poor sensitivity of
sputum cytology can be explained by an inade-
quate sample of sputum collected for cytological
examination. Induction of sputum in subjects who
are not able to produce sputum spontaneously or
who produce inadequate samples of sputum may
solve the problem. In addition, sputum induction
may presumably provide more robust samples and
increase sensitivity of cytological examination in
subjects who produce samples of sputum suitable
for analysis. Advances in improved yield of ex-
pectoration and improved methods of evaluating
sputum are crucial points for future investigations.
Sarcoidosis
Sarcoidosis is a systemic granulomatous dis-
ease characterised by a T-helper-1 response with
accumulation of CD4+ lymphocytes and activated
macrophages in the lungs and affected organs, re-
sulting in granuloma formation [72]. The immune
response in the pathogenesis of sarcoidosis is me-
diated by alveolar macrophages and lymphocytes
making these two cells biomarkers of the disease.
Some studies have demonstrated that sputum of a
patients with sarcoidosis is characterised by rela-
tively high lymphocyte counts [73]. However, the
evidence of other biomarkers is missing. Identifi-
cation of mediators secreted by lymphocyte in spu-
tum of patients with sarcoidosis is the objective for
future research.
Fig. 5. - Cytospin of a patient with COPD. Neutrophils are prevailing.
Magnification 100X.
Fig. 6. - Cytospin of a patient with asthma. Eosinophils are abundant.
Magnification 100X.
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Conclusions
As seen above induced sputum is a validated
technique that can be applied in several pulmonary
diseases both for research and diagnosis and it has
potentials for a large-scale application in several
clinical settings.
It is important to consider the most relevant
advantages and disadvantages of the discussed
technique. Induced sputum has several pro’s in-
cluding reproducibility of differential cell count on
cytospins, the possibility to sample multiple bio-
markers, its validity as a tool for assessment of an-
ti-inflammatory therapy and its relative non-inva-
siveness.
However a number of cons have to be taken in-
to account. Sputum induction and processing are
expensive and time-consuming procedures that re-
quire well-equipped laboratories with trained per-
sonnel and rescue medication promptly available.
Moreover, adequate samples cannot be ob-
tained from all the subjects (80% on average) and
sputum induction should not be performed in pa-
tients with severe persistent bronchocostiction
and/or co-morbidities such as cardiovascular dis-
orders.
Induced sputum should not be repeated over a
short-term period (< 48/h) as it may affect the
composition of inflammatory cells and mediators
in the airways [74, 75].
Finally, the processing of sputum with
dithiotreitol may affect the measurement of fluid-
phase mediators for its action on disulphide bonds
[76-78] and the lack of a validated dilution factor
may lead to incomparable measurements among
authors.
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